Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2019

Neuroinflammation and myelin status in Alzheimer’s disease,
Parkinson’s disease, and normal aging brains: A small sample
study
Fei Han
Washington University School of Medicine in St. Louis

Richard J. Perrin
Washington University School of Medicine in St. Louis

Qing Wang
Washington University School of Medicine in St. Louis

Yong Wang
Washington University School of Medicine in St. Louis

Joel S. Perlmutter
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Han, Fei; Perrin, Richard J.; Wang, Qing; Wang, Yong; Perlmutter, Joel S.; Morris, John C.; Benzinger,
Tammie L. S.; and Xu, Jinbin, ,"Neuroinflammation and myelin status in Alzheimer’s disease, Parkinson’s
disease, and normal aging brains: A small sample study." Parkinson's Disease. 2019,. 7975407. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7954

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Fei Han, Richard J. Perrin, Qing Wang, Yong Wang, Joel S. Perlmutter, John C. Morris, Tammie L. S.
Benzinger, and Jinbin Xu

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/7954

Hindawi
Parkinson’s Disease
Volume 2019, Article ID 7975407, 12 pages
https://doi.org/10.1155/2019/7975407

Research Article
Neuroinflammation and Myelin Status in Alzheimer’s Disease,
Parkinson’s Disease, and Normal Aging Brains: A Small
Sample Study
Fei Han,1 Richard J. Perrin,2,3 Qing Wang,1 Yong Wang,1 Joel S. Perlmutter,1,4,5,6,7
John C. Morris,4 Tammie L. S. Benzinger,1 and Jinbin Xu 1
1

Department of Radiology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
Department of Pathology & Immunology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis,
MO 63110, USA
3
Knight Alzheimer Disease Research Center, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis,
MO 63110, USA
4
Department of Neurology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
5
Department of Neuroscience, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
6
Department of Physical Therapy, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis,
MO 63110, USA
7
Department of Occupational Therapy, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis,
MO 63110, USA
2

Correspondence should be addressed to Jinbin Xu; jinbinxu@wustl.edu
Received 2 April 2019; Revised 6 June 2019; Accepted 12 June 2019; Published 4 July 2019
Academic Editor: Hélio Teive
Copyright © 2019 Fei Han et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Microglia and astrocytes play important roles in mediating the immune processes and nutritional support in the central
nervous system (CNS). Neuroinﬂammation has been indicated in the progression of neurodegenerative diseases Alzheimer’s disease (AD) and Parkinson’s disease (PD). Chronic neuroinﬂammation with sustained activation of microglia and
astrocytes may aﬀect white matter tracts and disrupt communication between neurons. Recent studies indicate astrogliosis
may inhibit remyelination in demyelinating disorders such as multiple sclerosis. In this study, we investigated the relationship between neuroinﬂammation and myelin status in postmortem human brain tissue (n � 15 including 6 AD, 5 PD,
and 4 age-matched, neurologically normal controls (NC)). We conducted systematic and quantitative immunohistochemistry for glial ﬁbrillary acidic protein (GFAP), ionized calcium-binding adaptor molecule 1 (Iba1), amyloid beta, and
highly phosphorylated tau (tauopathy). White matter intactness was evaluated by myelin and axon staining in adjacent brain
tissue sections. Eight of 15 cases (4 AD, 3 PD, and 1 NC) showed increased immunoreactivity for microglia and astrocytes in
the white matter that connects striatum and cortex. Quantitative analysis of these 8 cases showed a signiﬁcant negative
correlation between GFAP (but not Iba-1) and myelin (but not axon) staining in white matter (r2 � 0.78, p < 0.005). Tau, but
not amyloid beta plaques, is signiﬁcantly higher in AD vs. PD and NC. Tau burden increases with age in AD cases. These
observations indicate that astrocytosis in white matter is associated with loss of myelin in AD, PD, and normal aging and
that tau is a potent biomarker for AD.

1. Introduction
White matter disease is a common pathology involved in the
dementia of Alzheimer’s disease [1, 2], multiple sclerosis [3],
and cerebrovascular disease [4]. Brain white matter is

generally categorized into two types: deep and superﬁcial
white matter. Compared with deep white matter, superﬁcial
white matter undergoes later myelination and has less wraps
around the axon. These features render it vulnerable to
aging- or injury-related impairment [5]. Moreover,
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superﬁcial white matter has complex connectivity with
cortical ﬁbers and contributes to information processing
and integration [6]. This disorder of superﬁcial white
matter has been implicated in cognitive dysfunction, such
as Alzheimer’s disease, schizophrenia, and Huntington’s
disease [7]. Astrocytes are the most numerous cell type in
the CNS and perform many physiological functions in this
system. These functions include maintaining homeostasis
at the synapse, regulation of neuronal signaling, protecting
neurons from oxidative damage, and assisting in the
formation of myelin. Astrocytes not only control proliferation and migration of oligodendrocytes but also
regulate the timing of myelination [8]. Some studies
suggest that GFAP knockout mice have more extensive
dysfunction in the white matter than in the gray matter,
indicating that astrocytes play crucial roles in facilitating
and maintaining normal myelination [9]. However,
overactivated astrocytes also secrete factors associated
with the inhibition of myelination, such as transforming
growth factor (TGF-α) and bone morphogenetic protein
(BMP) 2/4 [10].
In addition, cerebral amyloid-beta (Aβ), neuroﬁbrillary tangles (abnormal tau), and neuroinﬂammation are all
involved in AD pathology [11]. Dysfunctional perivascular
cells also play a pathological role in neurodegenerative
diseases and cerebral vascular diseases [12]. In the current
study, we examined 15 autopsied human brains that included 5 cases of Parkinson disease (PD), 6 cases of
Alzheimer disease (AD), and 4 cases of age-matched
cognitively normal controls (NC) using immunohistochemistry (IHC) staining for GFAP and Iba1, Aβ and
phosphorylated tau, and α-SMA, as well as myelin and
axon staining. We found that cases with high GFAP expression (4 AD, 3 PD, and 1 NC) in superﬁcial white
matter have a signiﬁcantly negative correlation with myelin loss, whereas cases with low GFAP expression (2AD, 2
PD, and 3 NC) do not present negative correlation.
Phosphorylated tau was highly expressed and increased
with age in AD, and tau burden was signiﬁcantly higher
than Aβ in AD cases. These data suggest that chronic
inﬂammation-induced astrocytosis in superﬁcial white
matter might be associated with myelin impairment and
disease progression in these patients. Furthermore, it
suggests that tau is a more potent biomarker than Aβ for
aging-associated dementia in AD.

2. Materials and Methods
2.1. Cases. Postmortem human brain tissue samples including six AD, ﬁve PD, and four age-matched cognitively
healthy controls (3 female and 12 male) were obtained
from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (AD and control cases) and the
Movement Disease Research Center (PD cases), Department of Neurology, Washington University School of
Medicine (Table 1). Written consent from the participant
or the next-of-kin was obtained for brain removal, following local Institutional Review Board policies and
procedures at Washington University in St. Louis.
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2.2. Tissue Collection, Staining, and Immunohistochemistry.
Brieﬂy, brains were removed at the time of autopsy and the
left hemispheres were ﬁxed in 10% neutral-buﬀered formalin
for 2 weeks or more before samples were processed for
histology and embedded in paraﬃn. Histologic sections
were cut at 6 μm thickness and mounted on glass slides.
Histologic stains included hematoxylin and eosin, Luxol
fast blue and Cresyl echt violet (NeuronMyelinStain), and
Bielschowsky silver staining (Hitobiotec Corp. Kingsport,
TN, USA). For immunohistochemistry, all specimens
underwent heat-induced antigen retrieval (0.01 M citrate
buﬀer at pH 6.0) and were immunostained by the EnVision
method. Specimens were then incubated overnight at 4°C
with rabbit monoclonal anti-GFAP antibody (1 : 250 dilution, Abcam Inc. MA, USA), rabbit polyclonal anti-Iba1
antibody (1 : 250 dilution, Wako Chemicals USA, Inc), and
rabbit polyclonal to alpha smooth muscle actin antibody (1 :
100 dilution, Abcam Inc. MA, USA). Avidin-biotin
complex (VECTASTAIN UNIVERSAL ELITE ABC KIT)
was used for immunohistochemical staining of Aβ (10D5,
Elan Pharmaceuticals, San Francisco, CA, USA) and
phosphorylated tau (PHF-1, generous gift of Dr. Peter
Davies, Feinstein Institute for Medical Research, Manhasset, NY, USA), phosphorylated TDP-43 (Cosmo Bio
USA Inc, Carlsbad, CA, USA), phosphorylated α-synuclein
(Wako Chemicals USA Inc, Richmond, VA, USA), and PBS
without the primary antibody for a negative control.
Specimens were then incubated with horseradish peroxidase-linked goat anti-rabbit or mouse secondary antibody
and ABC complex, followed by reaction with diaminobenzidine. No speciﬁc immunostaining was detected
in negative controls under these conditions. The positive
signaling for GFAP and Iba1 was located in the cytoplasm,
and their positive areas and densities of myelin and axon
were analyzed by VISIOPHARM imaging analytic software. The severity of Lewy body pathology was assessed
using the Braak et al.’s Parkinson’s disease staging scale
[13]. Alzheimer’s disease neuropathological changes were
assessed by the Braak staging method [14, 15].
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2.3. Statistical Analysis. All values are expressed as
mean ± SEM. Mann–Whitney nonparametric test and oneway analysis of variance (ANOVA) were used to identify
signiﬁcant diﬀerences in two or multiple comparisons.
Pearson correlation coeﬃcients and two-tailed hypothesis
test were used to evaluate correlation between two variables. All analyses were performed by GraphPad Prism
software. A level of p < 0.05 was considered statistically
signiﬁcant.

3. Results
3.1. Clinical Features of 15 Cases. As shown in Table 1, there
are 6 cases of AD, 5 cases of PD, and 4 cases of age-matched
neurologically normal controls, with the median age of 78
(69–93) years including 3 females and 12 males. There are
no signiﬁcant diﬀerence in the average age at death
(p > 0.8, Student’s t-test), postmortem interval (p > 0.19,
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Table 1: Demographic and neuropathological features of subjects with PD or AD and age-matched controls.
Gender

Onset
(years)

STN-DBS
(years)

Clinical cause
of death

84
87
73
86
76
83
93
85
76
75

F
M
M
M
M
F
M
M
M
M

67
72
58
63
66
69
81
75
67
67

0
0
0
0
75
0
0
0
0
0

69

M

60

0

78
78
78
91

M
M
F
M

N/A
N/A
N/A
N/A

0
0
0
0

Inanition
Inanition
Unknown
Inanition
Myocardial infarction
Inanition
Inanition
Inanition
Inanition
Myocardial infarction
Non-Hodgkin’s
lymphoma
Pneumonia
Metastatic prostate cancer
Duodenal cancer
Septicemia

Age
(year)

Brain
weight
(g)
1190
1300
1500
1270
1400
900
1450
1130
1384
1430

PMI
(h)

Braak
PD

Braak
Aβ

Braak
Diagnosis
NFT

8
7.7
52
15
40.5
10.5
16
16.5
28
6.5

5
5
5
4
5
0
0
0
0
0

0
1
1
1
0
5
5
5
4
3

2
1
2
2
1
5
6
5
6
3

PD
PD
PD
PD
PD
AD
AD
AD
AD
AD

1350

21

0

4

6

AD

1220
1208
1290
1250

14
87
15.7
16

0
0
0
0

0
0
0
0

1
1
2
2

NC
NC
NC
NC

STN-DBS, subthalamic nucleus-deep brain stimulation; PMI, postmortem interval; Braak PD, Braak Lewy body stages in Parkinson’s disease (range: 1–6);
Braak Aβ, Braak beta-amyloid plaque stage; Braak NFT, Braak neuroﬁbrillary tangle stage; PD, Parkinson’s disease; AD, Alzheimer’s disease; NC, agematched cognitively intact normal control.

Student’st-test), or brain weight (p > 0.28, Student’s t-test)
among PD, AD, and NC. Only one patient with PD had
bilateral subthalamic nucleus-deep brain stimulation.
All the white matter regions originating from these
samples were identiﬁed as superﬁcial white matter by histological observation (Figure 1).
3.2. Expression of GFAP and Iba1 in the Astrocytosis Group
and Nonastrocytosis Group. The expression of GFAP and
Iba1 was detected by immunohistochemistry staining. The
activated astrocytes and microglia are shown in Figure 2(a).
The quantitative expression of GFAP and Iba1, shown in
Figures 2(b) and 2(c), revealed signiﬁcantly higher expression of GFAP (but not Iba1) in the superﬁcial white matter of
the astrocytosis group compared to the nonastrocytosis
group (∗ p < 0.05).
3.3. Diﬀerent Functional States of Microglia Were Observed in
AD, PD, and NC Samples. Compared to cognitive intact
healthy control, more dystrophic and activated microglia
were spotted in AD and PD patients. These ﬁndings suggest
not only the activation but also the underlying degenerative
process of microglia contribute to pathologenesis of AD and
PD (Figure 3).
3.4. Negative Correlation between the GFAP Expression and
Myelin Density in the Superﬁcial White Matter of Astrocytosis
Group (4 AD, 3 PD, and 1 NC). After classifying these cases
into two groups based on expression of GFAP in superﬁcial
white matter, the astrocytosis group which has high GFAP
expression and includes 4 AD, 3 PD, and 1 NC cases and the
nonastrocytosis group which includes 2 PD, 2 AD, and 3 NC
cases. Representative images of AD, PD, and NC patients for
GFAP, Iba1, and myelin and axonal staining are shown in

Figures 4(a) and 4(c). As shown in Figures 4(b) and 4(d), the
expression of GFAP signiﬁcantly inversely correlates with
myelin densities of superﬁcial white matter in the astrocytosis group (R2 � 0.78, p � 0.003), but GFAP expression does
not correlate with myelin densities of superﬁcial white
matter in the nonastrocytosis group (R2 � 0.32, p � 0.18).
However, as shown in Figure 5(a), the expression of GFAP
does not signiﬁcantly correlate with axon density in the
astrocytosis group (R2 � 0.0007, p � 0.35) nor in the nonastrocytosis group (R2 � 0.33, p � 0.18), which suggest that
astrocyte may also contribute axon generation in white
matter. Although a high but not signiﬁcant expression of
Iba1 was detected in the astrocytosis group compared to the
nonastrocytosis group, the expression status of Iba1 does not
correlate with myelin or axon densities whether in the
astrocytosis group or the nonastrocytosis group
(Figures 5(c)–5(f )).
The expression of GFAP and Iba1 in diﬀerent regions of
6 cases of AD, 5 cases of PD, and 4 cases of age-matched
cognitively intact controls.
We also analyzed the expression of GFAP and Iba1 in
superﬁcial white matter, cortical gray matter, and striatum in
these patients (6 AD, 5 PD, and 4 NC). As shown in
Figures 6(a)–6(h), there is no signiﬁcant diﬀerences in expression of GFAP and Iba1 in AD, PD, and NC groups in
diﬀerent regions (p > 0.05), probably due to small sample
limitation. Furthermore, we analyzed myelin and axon status
in superﬁcial white matter, there is no signiﬁcant diﬀerences
except mild decline of myelin sheath observed in PD
patients.
3.5. Tauopathy and Pericyte Status in 6 Cases of AD, 5 Cases of
PD, and 4 Cases of Age-Matched Cognitively Intact Controls.
Hyperphosphorylated tau was identiﬁed by labeling with a
PHF mouse monoclonal antibody, and tau was found to be
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(a)

(b)

(c)

(d)

(e)

(f )

Figure 1: Myelin staining in the representative AD, PD, and age-matched cognitive intact controls (NC) cases. (a, c, e) The connected ﬁne
ﬁbers between the junction of subcortical white and gray matter from AD, PD, and NC, respectively (the bars represent a 200 μm scale; the
insets show a gross view, and the small squares indicate the zoomed regions). (b, d, f ) The ﬁbers in the subcortical white matter from the
same AD, PD, and NC cases, respectively. The ﬁbers are short and small in diameter, they are arranged in complex cross-linking pattern (the
bars represent a 200 μm scale).

extensively expressed in all six AD cases. Tau was not, or
rarely, expressed in PD and NC cases. The positive areas of
tau in AD cases were primarily localized in the gray matter
and junction between gray and white matter. Intracellular
tau expression was found to be localized in the cytoplasm of
neurons and gliocytes. Phosphorylated tau was highly
expressed in AD cases. We classiﬁed these cases into two age
groups (under 80 and over 80). Tau expression was observed
to be signiﬁcantly higher in the >80 group than in the <80
group (Figure 7). Amyloid beta (Aβ) was labeled by a 10D5
antibody, and Aβ plaque burden was found to be signiﬁcantly lower than tau in these AD cases (Figure 7). Dysfunction of perivascular cells was also reported to be

involved in the neuropathological diseases, such as Alzheimer’s disease and multiple sclerosis. Here, we investigated pericytes status by labeling α-SMA, a speciﬁc
marker for pericytes. No perivascular cytopathology was
identiﬁed in these cases (Figure 8). However, we cannot
exclude the presence of perivascular cytopathology in other
brain regions due to our sample limitations.

4. Discussion
Chronic neuroinﬂammation, mediated by reactive astrocytes and activated microglia, plays an important role
in the progression of neurodegenerative diseases, such as
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White matter

Gray matter

Striatum

GFAP

Iba1

0.8

#

0.6
0.4
0.2
0.0

Astrocytosis

Nonastrocytosis

Relative Iba1 expression in SWM

Relative GFAP expression in SWM

(a)

0.04
0.03
0.02
0.01
0.00

(b)

Astrocytosis

Nonastrocytosis

(c)

Figure 2: Astrocytes and microglia in the striatal tissue sections using GFAP and Iba1 antibodies. (a) Representative images of activated
astrocytes and microglia in white matter, gray matter, and striatum. The activated astrocytes showed enlarged cell bodies and enlongated
fibers, while activated microglia showed meatball-like appearance with enlarged cell bodies and shortened processes. The scale bar
represents 100 μm. (b, c) The quantitative analysis of the GFAP and Iba1 expression in white matter in the astrocytosis and the nonastrocytosis groups. The bars represent mean ± SEM. ∗ represents p < 0.05.

(a)

(b)

Figure 3: Continued.
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(c)

(d)

(e)

(f )

Figure 3: Different morphologies of microglia in AD, PD, and NC. (a, b) Dystrophic microglia from striatal white matter and cortex of two
AD patients which displayed twisted or fragmented processes and cell body enlargement. (c, d) Activated and dystrophic microglia from
striatum of two PD patients which showed cell body enlargement and fragmented processes. (e, f ) Resting microglia from striatum of two
health controls which showed the small cell body with highly branched processes. The scale represents 400 μm.
Iba1

Myelin

Axon

Astrocytosis group
Relative GFAP expression in SWM

GFAP
AD

PD

NC

0.8
R2 = 0.777
p = 0.003

0.7
0.6
0.5
0.4

0.0

(a)

0.2

0.4
0.6
Average myelin density
(b)

Figure 4: Continued.

0.8

1.0
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Nonastrocytosis group
0.5
Relative GFAP expression in SWM

AD

PD

NC

R2 = 0.324
p = 0.182

0.4
0.3
0.2
0.1
0.0

0.0

0.2

0.4
0.6
Average myelin density

(c)

0.8

(d)

Figure 4: GFAP, Iba1, myelin, and axon staining and correlation analysis between GFAP expression and myelin density. Left panel shows
the representative IHC images of GFAP, Iba1, myelin, and axon staining in the striatal tissue sections from AD, PD, and NC cases in the
astrocytosis (a) and the nonastrocytosis group (c). Right panel shows the correlation between GFAP expression and myelin density in the
astrocytosis (b) and the nonastrocytosis (d) groups.
Astrocytosis group

Nonastrocytosis group
0.5
Relative GFAP expression in SWM

Relative GFAP expression in SWM

0.8
R2 = 0.0007

0.7

0.6

0.5

0.4

0.0

0.1

0.2
0.3
Average axon density

0.4

R2 = 0.327

0.4
0.3
0.2
0.1
0.0
0.00

0.02

0.06
0.04
Average axon density

(a)

(b)

Astrocytosis group

Nonastrocytosis group
0.025

R2 = 0.067

Relative Iba1 expression in SWM

Relative Iba1 expression in SWM

0.04
0.03
0.02
0.01
0.00

0.0

0.2

0.4
0.6
Average myelin density

0.08

0.8

1.0

R2 = 0.004

0.020
0.015
0.010
0.005
0.000

0.0

(c)

0.2

0.4
0.6
Average myelin density
(d)

Figure 5: Continued.
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Astrocytosis group

Nonastrocytosis group
0.025

R2 = 0.0001

Relative Iba1 expression in SWM

Relative Iba1 expression in SWM

0.04
0.03
0.02
0.01
0.00

0.0

0.1

0.2
0.3
Average axon density

R2 = 0.105

0.020
0.015
0.010
0.005
0.000
160

0.4

180

(e)

200
220
Average axon density

240

(f)

0.5

0.8
Relative GFAP expression in SWM

Relative GFAP expression in striatum

Figure 5: Correlation analysis between GFAP and Iba1 staining with axon and myelin densities. (a, b) The correlation between the
expression of GFAP and axon densities in the astrocytosis and nonastrocytosis group. (c, d) The correlation between the expression of Iba1
and myelin densities in the astrocytosis and nonastrocytosis group. (e, f ) The correlation between the expression of Iba1 and axon densities
in the astrocytosis and nonastrocytosis group.

0.4
0.3
0.2
0.1
0.0

AD

PD

NC

0.6

0.4

0.2

0.0

AD

0.6
0.4
0.2
0.0

AD

NC

PD

NC

(b)

0.8

Relative Iba1 expression in striatum

Relative GFAP expression in gray matter

(a)

PD

PD

NC
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0.03
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0.00

(c)

AD
(d)

Figure 6: Continued.
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Relative Iba1 expression in gray matter

Relative Iba1 expression in SWM

0.04
0.03
0.02
0.01
0.00

AD

PD

NC

0.015

0.010

0.005

0.000

AD

(e)

NC

PD

NC

(f )

240
Axon intensity in SWM

80
Myelin intensity in SWM

PD

70

60

50

40

220
200
180
160
140

AD

PD

NC

(g)

AD
(h)

Figure 6: Relative GFAP and Iba1 expression and myelin and axon status in PD, AD, and age-matched cognitive intact controls (NC).
(a) Expression of GFAP in the striatum. (b) Expression of GFAP in white matter. (c) Expression of GFAP in gray matter. (d) Expression of
Iba1 in the striatum. (e) Expression of Iba1 in white matter. (f ) Expression of Iba1 in gray matter. (g) Myelin status in AD, PD, and NC.
(h) Axon status in AD, PD, and NC. The bars represent mean ± SEM.

(a)

(b)

Figure 7: Continued.
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60

Tau expression in AD gray matter
Average positive signal per lower field

Average positive cell number per lower field

10

p < 0.0001

40

20

0

Age > 80

Age < 80
(c)

p = 0.0020

60

40

20

0

Aβ

Tau
(d)

Figure 7: Abnormal tau expression in AD patients. (a) Neurofibrillary tangle deposition in a 75-year-old male patient. (b) Neurofibrillary
tangle deposition in a 93-year-old male patient (insets represent gross image, the small squares indicate the zoomed regions, and the bars
represent a 200 μm scale). (c) Quantitative analysis of tau expression in six AD cases. (d) Quantitative analysis of tau and Aβ expression in
the gray matter of six AD cases.

(a)

(b)

(c)

(d)

(e)

(f )

(g)

(h)

(i)

Figure 8: Immunohistochemical staining of α-SMA in AD, PD, and age-matched cognitively normal controls (NC) cases. The positive
staining (brown color) were localized in the perivascular area (pericytes). The nucleus was stained by hematoxylin. The bars represent a
100 μm scale. (a) AD1, (b) AD2, (c) AD3, (d) PD1, (e) PD2, (f ) PD3, (g) NC1, (h) NC2, (i) NC3.

Parkinson’s disease and Alzheimer’s disease. In this study,
we assessed neuroinflammation in the striatum and associated cortical gray matter and white matter from 15

postmortem human brains including 6 cases of AD, 5
cases of PD, and 4 neurologically intact age-matched
controls. Although our data suggest that there is a trend
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that AD cases (with high burden of beta amyloid and tau)
have more neuroinﬂammation than PD and control cases,
we found no signiﬁcant diﬀerences for activation and
proliferation of astrocytes and microglia either in cortical
gray matter, superﬁcial white matter, or striatum among
PD, AD, and controls. This is consistent with translocator
protein binding (TSPO) or previous peripheral benzodiazepine receptor (PBR) quantitative autoradiography
studies using [3H]PK11195 and [3H]PBR28 in postmortem frozen human brains; TSPO binding density was
found to be not signiﬁcantly diﬀerent among AD (n � 7),
dementia with Lewy bodies (DLB) disease (n � 5), or
cognitively intact age-matched controls (n � 8) in these
brain regions [16]. However, some cases in the current
study (4 AD, 3 PD, and 1 NC) showed a signiﬁcantly
higher expression of GFAP in the superﬁcial white matter
(>0.5 positive staining area), in comparison to the other
cases (2 AD, 2 PD, and 3 NC) (<0.4 positive staining area).
Based on this diﬀerence, we classiﬁed these cases into two
groups: astrocytosis (4 AD, 3 PD, and 1 NC) and nonastrocytosis (2 AD, 2 PD, and 3 NC). Staining of myelin
and axon was performed to investigate the relationships
between the activation of glia cells (astrocyte and
microglia) and neurodegeneration, as reﬂected by axonal
and myelin integrity in the subcortical-striatal superﬁcial
white matter. We found that GFAP expression signiﬁcantly negatively correlated with myelin density in superﬁcial white matter in the astrocytosis group, but not in
the nonastrocytosis group. In contrast, Iba1 staining did
not correlate signiﬁcantly with myelin density in either
group.
Myelin sheath can boost neural transduction via the
node of Ranvier by insulating nerve cell axons in the central
and peripheral nervous systems. Damaged myelin sheath
could be a biomarker for the early-stage axon degeneration.
It has been reported that demyelination could induce axon
abnormalities by reducing axon caliber, abnormal neuroﬁlament distribution, and increasing mitochondria number [17–19]. However, a study posited that axonal
degeneration could occur independently from myelin loss
[20]. Here, we also investigated axon density in superﬁcial
white matter and evaluated its association with the expression of GFAP or Iba1 and myelin densities in superﬁcial white matter. Myelin density did not signiﬁcantly
correlate with axon density in all 15 cases (data not shown),
nor did axon density signiﬁcantly correlate with GFAP or
Iba1 expression.
Tau pathology has been a hallmark of Alzheimer’s diseases (AD). Tau exists as monomers, paired helical ﬁaments
(PHFs), and straight ﬁlaments in AD [21]. Here, we investigated tau status by labeling with a PHF antibody in the
striatal sections of AD, PD, and NC cases. Phosphorylated
tau was highly expressed in all AD patients, especially in the
age >80 group, compared to PD and NC cases. Furthermore,
we also conducted amyloid beta immunohistochemistry in
the adjacent sections of all cases. No concurrent expression
of phosphorylated tau and amyloid beta was found in these
cases except for one case, 83-year-old female. This case had a
decent expression of amyloid beta in the gray matter area.
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The overall expression of amyloid beta was signiﬁcantly
lower compared to phosphorylated tau in all AD cases. No
obvious expression of amyloid beta was observed in all PD
and NC cases. These data support the hypothesis that tau
pathology is independent of amyloid beta in the neurodegenerative diseases and that neuroﬁbrillary tangles (tauopathy) are a better biomarker for predicting cognitive
impairment in Alzheimer’s diseases.
Pericytes, the perivascular-specialized smooth muscle
cells, have multiple pathological functions in the brain.
Interactions between pericytes and endothelial cells are
important for the remodeling and maintenance of the
vascular system. Pericytes also regulate the neurotransmitter
transport and vascular permeability. Dysfunction of pericytes is involved in neuropathological diseases, such as
hypertension, diabetic retinopathy, and Alzheimer’s diseases
[12]. Here, in this study, we also evaluated pericyte status by
α-SMA staining. No obvious perivascular cytopathology was
observed in the cases we studied.
Patients with neurodegeneration disease often have
damage in the white matter, which is composed of axonal
ﬁbers interconnecting neurons in the brain [22]. White
matter damage, which includes demyelination and inﬂammation, is associated with cognitive dysfunction and is
one of the most important factors in the complex etiology of
AD [23, 24]. Our study suggests that chronic activation of
astrocytes and microglia may contribute to myelin sheath
loss and nerve ﬁber degeneration. Abnormal tau was highly
expressed in AD compared to PD and NC. Neuroﬁbrillary
tangles deposition is independent of plaques formation in
the course of AD. No dysfunctional pericytes were observed
in AD, PD and NC cases. Taken together, reactive astrocytes
may produce toxic eﬀects on myelin sheath and abnormal
tau has a better correlation with AD dementia than amyloid
beta.
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